(Q43991963)

English

A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors (English)

1 reference

Europe PubMed Central

28 November 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mitsune Tanimoto

10

object named as

Mitsune Tanimoto

1 reference

Europe PubMed Central

28 November 2017

Katsuyuki Kiura

3

object named as

Katsuyuki Kiura

1 reference

Europe PubMed Central

28 November 2017

2

object named as

Hiroshi Ueoka

1 reference

Europe PubMed Central

28 November 2017

Tomonori Moritaka

7

object named as

Tomonori Moritaka

1 reference

Europe PubMed Central

28 November 2017

5

object named as

Nagio Takigawa

1 reference

Europe PubMed Central

28 November 2017

9

object named as

Mine Harada

1 reference

Europe PubMed Central

28 November 2017

Yoshihiko Segawa

6

object named as

Yoshihiko Segawa

1 reference

Europe PubMed Central

28 November 2017

Shunkichi Hiraki

8

object named as

Shunkichi Hiraki

1 reference

Europe PubMed Central

28 November 2017

Tsuyoshi Kodani

1

object named as

Tsuyoshi Kodani

1 reference

Europe PubMed Central

28 November 2017

author name string

Masahiro Tabata

4

1 reference

Europe PubMed Central

28 November 2017

publication date

1 June 2002

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

36

1 reference

Europe PubMed Central

28 November 2017

3

1 reference

Europe PubMed Central

28 November 2017

313-319

1 reference

Europe PubMed Central

28 November 2017

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900008-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(02)00008-9

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43991963&oldid=2105386056"